Long-Term Safety of Siltuximab in Patients With Idiopathic Multicentric Castleman Disease: A Prespecified, Open-Label, Extension Analysis of Two Trials

The Lancet Haematology - United Kingdom
doi 10.1016/s2352-3026(19)30257-1
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Elsevier BV

Related search

Siltuximab: A Targeted Therapy for Idiopathic Multicentric Castleman Disease

Immunotherapy
OncologyAllergyImmunology
2016English

FDA Approval: Siltuximab for the Treatment of Patients With Multicentric Castleman Disease

Clinical Cancer Research
Cancer ResearchOncology
2015English

Long-Term Safety and Tolerability of Oral Tofacitinib in Patients With Crohn’s Disease: Results From a Phase 2, Open-Label, 48-Week Extension Study

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Predictors of Response to Anti-Il6 Monoclonal Antibody Therapy (Siltuximab) in Idiopathic Multicentric Castleman Disease: Secondary Analyses of Phase II Clinical Trial Data

British Journal of Haematology
Hematology
2018English

Clinicopathologic Characteristics of 342 Patients With Multicentric Castleman Disease in Japan

Modern Rheumatology
MedicineRheumatology
2020English

SAT0236 Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral Jak-1 Inhibitor in Patients With Rheumatoid Arthritis in an Open Label Extension Study

2018English

Long-Term Safety of Adalimumab in Clinical Trials in Adult Patients With Crohn's Disease or Ulcerative Colitis

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Biologic Agents in the Treatment of Multicentric Castleman Disease

Turkish Thoracic Journal
PulmonaryRespiratory Medicine
2018English

Long-Term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-Center, Open-Label, Phase IIIb Study

Clinical Therapeutics
Pharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy